Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment

Chin Med J (Engl). 2023 Nov 20;136(22):2738-2740. doi: 10.1097/CM9.0000000000002888. Epub 2023 Oct 25.

Authors

Yongquan Peng¹, Xujian Cao¹, Yating Wang¹, Weiwei Yu², Ziwei Zeng², Min Wang²

Affiliations

¹ Graduate Collaborative Training Base of the First Hospital of Changsha, University of South China, Hengyang, Hunan 421001, China.
² Institute of HIV/AIDS, First Hospital of Changsha, Changsha, Hunan 410000, China.

No abstract available

Publication types

Letter

MeSH terms

Anti-HIV Agents* / therapeutic use
Emtricitabine / therapeutic use
HIV Infections* / drug therapy
Humans
Tenofovir / therapeutic use

Substances

tenofovir alafenamide
bictegravir
efavirenz
Tenofovir
Emtricitabine
Anti-HIV Agents